<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710721</url>
  </required_header>
  <id_info>
    <org_study_id>ProstateDiet</org_study_id>
    <nct_id>NCT02710721</nct_id>
  </id_info>
  <brief_title>Fasting and Nutritional Therapy in Patients With Advanced Metastatic Prostate Cancer</brief_title>
  <official_title>Clinical Study on the Efficacy of Fasting and Nutritional Therapy as a Complementary Treatment of Advanced Metastatic Prostate Cancer Undergoing Chemotherapy - an Exploratory Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is a first evaluation of the effectiveness of intermittent fasting as a
      supplementary therapy in patients with CRPC or hormone-sensitive prostate cancer with high
      metastatic load (1≥ visceral and ≥4 osseous metastases) in respect to quality of life,
      reduction of side effects and possible reduction in tumor progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer is in Germany with approximately 25% of all cancers the most common cancer
      among man. Assumably there will be an increase in prostate cancer in the next few years
      because of demographic factors. The progressive metastatic prostate cancer often develops an
      androgen resistance. This so-called Castration-Resistant Prostate Cancer (CRPC) is not
      responsive to androgen deprivation therapy. Depending on symptoms and progression first-line
      chemotherapy - docetaxel and abiraterone are available.

      Intermittent fasting as a form of caloric restriction has been studied most extensively
      experimentally in recent years. It showed consistent beneficial effects on relevant
      inflammatory and oncological pathways. In the field of preclinical oncology research groups
      have recently focused on intermittent fasting with chemotherapeutic treatment and promising
      experimental data have been published. In summary, the combination of fasting and
      chemotherapy was more effective in various cancer animal models than chemotherapy alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FACT-P/-Taxane/-An sum score</measure>
    <time_frame>Assessment day 0 (baseline) and 7 days after each of 6 chemotherapies (study weeks 1,4,7,10,13,16)</time_frame>
    <description>summarized change of FACT score from baseline to day 8 after each chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FACT-P/-Taxane/-An sum score</measure>
    <time_frame>Assessment day 0 (baseline) and 3 and 6 months after day 0</time_frame>
    <description>Change of score after 3 and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS</measure>
    <time_frame>Assessment day 0 (baseline) and 7 days after each of 6 chemotherapies (study weeks 1,4,7,10,13,16) and after 3 and 6 months after study day 0</time_frame>
    <description>Summarized change of score for all time Points</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Differential blood count</measure>
    <time_frame>Assessment day 0 (baseline) and 7 days after each of 6 chemotherapies (study weeks 1,4,7,10,13,16) and after 3 and 6 months after study day 0</time_frame>
    <description>Summarized changes of blood count</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensity of chemotherapy- related side effects</measure>
    <time_frame>Assessment day 0 (baseline) and 7 days after each of 6 chemotherapies (study weeks 1,4,7,10,13,16)</time_frame>
    <description>Group difference of summarized frequency and intensity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fasting</condition>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60h-modified fasting (36h before and 24h after chemotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mediterranean diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fasting</intervention_name>
    <description>Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.</description>
    <arm_group_label>Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CRPC or hormone-sensitive prostate cancer with high metastatic load

          -  Cancer is treated to guidelines conventionally with chemotherapy or with a combination
             of hormone therapy and chemotherapy.

        Exclusion Criteria:

          -  Underweight (BMI &lt;20 kg/m2) or actual weight decrease &gt;2 kg or &gt;5 kg in the last 1 or
             3 months.

          -  Eating disorder

          -  Dementia

          -  Psychosis

          -  Terminal illness with a significant limitation of mobility and overall vitality

          -  Diabetes mellitus type 1

          -  Renal insufficiency stage &gt; 2, GFR &lt;60mlmin / 1.73 m2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Michalsen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Centrum Epidemiologie und Gesundheitsökonomie, CC1: Gesundheitswissenschaften</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Miller, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Centrum Chirurgische Medizin, CC 8 Klinik für Urologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ursula Steiner, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Centrum Chirurgische Medizin, CC 8 Klinik für Urologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Michalsen, Prof. Dr.</last_name>
    <phone>+49 30 80505 691</phone>
    <email>a.michalsen@immanuel.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité Centrum Chirurgische Medizin, CC 8 Klinik für Urologie</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Steiner, Dr.</last_name>
      <phone>+49 30 8445 2577</phone>
      <email>ursula.steiner@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Kurt Miller, Prof. Dr.</last_name>
      <phone>+49 30 8445 2575</phone>
      <email>kurt.miller@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Kurt Miller, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ursula Steiner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andreas Michalsen</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Fasting</keyword>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Complementary Therapies</keyword>
  <keyword>Urology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

